| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 01/01/2002 | US6335424 ribG |
| 01/01/2002 | US6335358 Lactacystin analogs |
| 01/01/2002 | US6335352 Administering heterocyclic cyanoguanidine derivatives as chemokine inhibitors |
| 01/01/2002 | US6335349 Agents that reduce levels of tumor necrosis factor; anticarcinogenic and antiinflammatory agents; treatment of autoimmune diseases |
| 01/01/2002 | US6335347 2-loratadine antiallergen |
| 01/01/2002 | US6335342 Azaindole derivatives, process for their preparation, and their use as antitumor agents |
| 01/01/2002 | US6335331 Antihistamines, antiallergens, brochodilator agents and antispasmodic agents |
| 01/01/2002 | US6335183 Stress proteins and uses therefor |
| 01/01/2002 | US6335020 Allergenic peptides from ragweed pollen |
| 01/01/2002 | US6335019 Methods for treating sensitivity to protein allergen using peptides which include a T cell epitope recognized by a T cell receptor specific for the protein allergen |
| 01/01/2002 | CA2056799C 1,4-dihydropyridine derivatives and methods of producing the same |
| 12/27/2001 | WO2001098508A2 Transgenic mice containing targeted gene disruptions |
| 12/27/2001 | WO2001098490A1 A g-protein coupled receptor |
| 12/27/2001 | WO2001098481A2 Renal regulatory elements and methods of use thereof |
| 12/27/2001 | WO2001098471A2 Human phosphodiesterases |
| 12/27/2001 | WO2001098357A2 Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations |
| 12/27/2001 | WO2001098354A2 Human receptors |
| 12/27/2001 | WO2001098353A2 Secreted proteins |
| 12/27/2001 | WO2001098351A2 G-protein coupled receptors |
| 12/27/2001 | WO2001098330A2 A RECOMBINANT CELL LINE EXPRESSING GPCRx11 AS A FUNCTIONAL RECEPTOR VALIDATED BY ANGIOPEPTIN AND USEFUL FOR SCREENING OF AGONISTS AND ANTAGONISTS |
| 12/27/2001 | WO2001098323A2 G-protein coupled receptors |
| 12/27/2001 | WO2001098299A1 Azaindole derivatives, process for their preparation, and their use as antitumor agents |
| 12/27/2001 | WO2001098295A1 Novel 1,3-dihydro-2h-indol-one derivatives, method for preparing same and pharmaceutical compositions containing them |
| 12/27/2001 | WO2001098291A2 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders |
| 12/27/2001 | WO2001098289A1 Novel non-psychotropic cannabinoids |
| 12/27/2001 | WO2001098286A1 Nitrosated and nitrosylated taxanes, compositions and methods of use |
| 12/27/2001 | WO2001098279A2 Bis-arylsulfones |
| 12/27/2001 | WO2001098278A1 Methods and compositions utilizing quinazolinones |
| 12/27/2001 | WO2001098272A1 Novel compounds |
| 12/27/2001 | WO2001098270A2 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| 12/27/2001 | WO2001098269A2 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| 12/27/2001 | WO2001098268A2 Piperidine amides as modulators of chemokine receptor activity |
| 12/27/2001 | WO2001098245A2 Triphenyl compounds as interleukin-4 antagonists |
| 12/27/2001 | WO2001097858A2 Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination |
| 12/27/2001 | WO2001097842A1 Curing method for pathologic syndrome and a medicinal preparation |
| 12/27/2001 | WO2001097841A2 Qs-21 and il-12 as an adjuvant combination |
| 12/27/2001 | WO2001097838A2 Adjuvants and processes to induce a specific type of immune response |
| 12/27/2001 | WO2001097837A1 Solubilised protein vaccines |
| 12/27/2001 | WO2001097825A2 High molecular weight extracts of convolvulus arvensis (field bindweed) and polygonum convolvulus (wild buckwheat) |
| 12/27/2001 | WO2001097795A2 Systems and methods for treating a mucosal surface |
| 12/27/2001 | WO2001085719A9 Ortho-substituted anthranilic acid amides and their use as medicaments |
| 12/27/2001 | WO2001066136A3 Microbial delivery system |
| 12/27/2001 | WO2001062282A3 Adjuvants for vaccines |
| 12/27/2001 | WO2001060349B1 Pharmacological agent comprising picolinic acid, fusaric acid and derivatives thereof. |
| 12/27/2001 | WO2001057042A3 4-pyridyl-and 2,4-pyrimidinyl-substituted pyrrole derivatives and their use in pharmacy |
| 12/27/2001 | WO2001053505A3 Herpes virus strains for gene therapy |
| 12/27/2001 | WO2001051608A3 Hybrid cells obtainable from antigen presenting cells |
| 12/27/2001 | WO2001049711A3 Nucleic acids encoding (poly)peptides having chips activity |
| 12/27/2001 | WO2001047549A3 Conjugate useful as building block for vaccine preparation |
| 12/27/2001 | WO2001046256A3 Vesicle trafficking proteins |
| 12/27/2001 | WO2001045680A3 Cd45 inhibitors |
| 12/27/2001 | WO2001044278A3 Antigen preparations |
| 12/27/2001 | WO2001043769A3 Antigen delivery |
| 12/27/2001 | WO2001035975A3 Treatment of subnormal bone mineral density |
| 12/27/2001 | WO2001034189A3 Vaccines for mycoplasma bovis and methods of use |
| 12/27/2001 | WO2001034170A3 Phytotherapeutic composition |
| 12/27/2001 | WO2000067626A3 Oat extracts: refining, compositions and methods of use |
| 12/27/2001 | US20010056183 Sulfonamides and derivatives thereof that modulate the activity of endothelin |
| 12/27/2001 | US20010056124 Such as 2-amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol, in free form or as salt to treat organ or tissue allo- or xeno-transplant rejection |
| 12/27/2001 | US20010056118 Induction of polymerization of tubulin and the stabilization of microtubules in cells by administering to the cancer cells an effective amount of dictyostatin-1 or derivatives or salt |
| 12/27/2001 | US20010056113 Methods for the inhibition of angiogenesis with 6-amino EM-12 |
| 12/27/2001 | US20010056103 Non-immunosuppressive, piperidino or pyrrolidino amide derivative has an affinity for an FKBP-type immunophilin, useful for treating Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, amyotrophic lateral sclerosis |
| 12/27/2001 | US20010056100 Carboxylic acid or tetrazole derivatives containing carbamate groups are useful for treating the conditions associated with the urinary tract, pain, inflammation, respiratory states, edema formation of hypotensive vascular diseases |
| 12/27/2001 | US20010056093 Olopatadine and emedastine and an ophthalmically acceptable polymeric quaternary ammonium compound as a preservative |
| 12/27/2001 | US20010056092 Diaminocyclobutene-3,4-dione derivatives, their preparation and use |
| 12/27/2001 | US20010056063 Method of treating or preventing type 1 diabetes by oral administration of insulin |
| 12/27/2001 | US20010056061 Eliminate the Bovine Spongiform Encephalopathy (BSE) risk by synthesizing a thymic peptide; short-chain peptides with a weighted quantity ratio and a pattern of amino acids characteristic of thymus tissue |
| 12/27/2001 | US20010055777 Potentiation of the immune response |
| 12/27/2001 | US20010055593 CD86 (B7) proteins; downmodulating an immune response comprising contacting immune cells with an antibody that binds to at least one B& molecule and a Rapamycin compound; treating autoimmune diseases such as Lupus erythematosis |
| 12/27/2001 | CA2805216A1 Antigenic polypeptides from staphylococcus |
| 12/27/2001 | CA2414015A1 Human receptors |
| 12/27/2001 | CA2413878A1 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders |
| 12/27/2001 | CA2413866A1 Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations |
| 12/27/2001 | CA2413454A1 A g-protein coupled receptor |
| 12/27/2001 | CA2413435A1 A recombinant cell line expressing gpcrx11 as a functional receptor validated by angiopeptin and useful for screening of agonists and antagonists |
| 12/27/2001 | CA2413421A1 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| 12/27/2001 | CA2413418A1 Piperidine amides as modulators of chemokine receptor activity |
| 12/27/2001 | CA2413358A1 Curing method for pathologic syndrome and a medicinal preparation |
| 12/27/2001 | CA2413274A1 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| 12/27/2001 | CA2412734A1 Renal regulatory elements and methods of use thereof |
| 12/27/2001 | CA2412484A1 G-protein coupled receptors |
| 12/27/2001 | CA2411978A1 Transgenic mice containing targeted gene disruptions |
| 12/27/2001 | CA2411865A1 Azaindole derivatives, process for their preparation, and their use as antitumor agents |
| 12/27/2001 | CA2411585A1 Novel non-psychotropic cannabinoids |
| 12/27/2001 | CA2411255A1 Novel compounds |
| 12/27/2001 | CA2411102A1 Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination |
| 12/27/2001 | CA2410632A1 Nitrosated and nitrosylated taxanes, compositions and methods of use |
| 12/27/2001 | CA2410447A1 Bis-arylsulfones |
| 12/27/2001 | CA2410208A1 Systems and methods for treating a mucosal surface |
| 12/27/2001 | CA2409781A1 Phosphodiesterases |
| 12/27/2001 | CA2409778A1 Secreted proteins |
| 12/27/2001 | CA2409776A1 G-protein coupled receptors |
| 12/26/2001 | CN1328571A Human monoclonal antibodies to CTLA-4 |
| 12/26/2001 | CN1328550A Oxazole compounds as prostaglandin E2 agonists or antagonists |
| 12/26/2001 | CN1328545A Hydrazine derivatives |
| 12/26/2001 | CN1328538A 2,4-pentadienoic acid derivatives having selective activity for retinoid X(RXR) receptors |
| 12/26/2001 | CN1328470A Chemokine receptor peptide vaccines for treatment and prevention of diabetes |
| 12/26/2001 | CN1328447A Process for producing particles with converted amorphous and/or meta-stable crystalline region into crystalline state |
| 12/26/2001 | CN1328057A Polypeptide-human FK506 bindin 12.32 and polynucleotide for coding it |
| 12/26/2001 | CN1328009A Polypeptide-Ras GTP enzyme activated protein 12 and polynucleotide for coding it |